Avior Bio Inc.
The startup has developed a drug delivery technology that bypasses first-pass metabolism and minimizes glucuronide metabolites excreted by the kidneys, specifically targeting pruritus in liver disease patients. This approach provides significant relief from associated symptoms such as insomnia, anxiety, and depression.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$4.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a drug delivery technology that bypasses first-pass metabolism and minimizes glucuronide metabolites excreted by the kidneys, specifically targeting pruritus in liver disease patients. This approach provides significant relief from associated symptoms such as insomnia, anxiety, and depression.